Related content

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer

By Barone Carlo   Basso Michele   Schinzari Giovanni   Pozzo Carmelo   Trigila Nunziatina   D'Argento Ettore   Quirino Michela   Astone Antonio   Cassano Alessandra  

Gastric Cancer, Vol. 10, Iss. 2, 2007-06 ,pp. : 104-111

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy - a phase I, dose-finding study

By Lortholary A.   Maillard P.   Delva R.   Boisdron-Celle M.   Perard D.   Vernillet L.   Besenval M.   Gamelin E.  

European Journal of Cancer, Vol. 36, Iss. 14, 2000-09 ,pp. : 1773-1780

Elsevier

Access to resources Recommend Favorite

Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor

By Cui Yuehong   Li Qian   Yu Yiyi   Chen Yong   Feng Yi   Wang Yan   Liu Tianshu  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 145-152

Springer Publishing Company

Access to resources Recommend Favorite

High efficacy of combination chemotherapy with S-1 and low-dose docetaxel for the treatment of highly advanced gastric cancer with peritoneal dissemination: A case report

By Zhu Lucheng   Luo Wenhua   Wei Juan   Zou Changlin  

Oncology Letters, Vol. 5, Iss. 5, 2013-05 ,pp. : 1509-1512

Spandidos Publications

Access to resources Recommend Favorite

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

By Wakui Hiroshi   Yamamoto Noboru   Nakamichi Shinji   Tamura Yousuke   Nokihara Hiroshi   Yamada Yasuhide   Tamura Tomohide  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 511-516

Springer Publishing Company

Access to resources Recommend Favorite